Aptamer-Mediated Cancer Gene Therapy Dongxi Xiang1*, Sarah Shigdar 1*, Greg Qiao2, Shu-Feng Zhou3, Yong Li4, Ming Q Wei5, 6 1 7 8 9** Liang Qiao , Hadi Al.Shamaileh , Yimin Zhu , Conglong Zheng , Chunwen Pu and Wei Duan1** 1School of Medicine, Deakin University, Pigdons Road, Waurn Ponds, Victoria, 3217, Australia. 2 Department of Chemical and Biomolecular Engineering, Melbourne School of Engineering The University of Melbourne, Parkville, Victoria 3010, Australia 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA. 4Cancer Care Centre, St George Hospital, Kogarah, NSW2217, and St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW2052, Australia 5Division of Molecular and Gene Therapies, Griffith Health Institute and School of Medical Science, Griffith University, Gold Coast, QLD 4222, Australia 6Storr Liver Unit, at the Westmead Millennium Institute, the University of Sydney at the Westmead Hospital, Westmead NSW, 2145, Australia 7Suzhou Key Laboratory of Nanobiomedicine, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, Jiangsu, China, 215123 8Department of Biology, Medical College, Dalian University, Liaoning, People’s Republic of China 9The Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Road, Dalian, Liaoning, The People's Republic of China, 116001. 1 * These authors contributed equally. ** Corresponding authors: E-mail:
[email protected] (C. Pu); or
[email protected] (W. Duan). 2 Abstract Cancer as a genetic disorder is one of the leading causes of death worldwide. Conventional anticancer options such as chemo- and/or radio-therapy have their own drawbacks and could not provide a cure in most cases at present.